{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:21Z","timestamp":1787316261075,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rituximab is an induction immunosuppressant essential for ABO-incompatible kidney transplantation (ABOi KT). However, studies on its dosing, which differs among countries and transplant centers, are lacking. Therefore, we retrospectively investigated the effectiveness of the induction dose of rituximab against patient mortality, graft failure, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We included the studies referring to at least 2 of eligible induction doses (200\u200amg, 200\u2013500\u200amg, or 500\u200amg) of rituximab during ABOi KT and relevant outcomes such as patient survival, graft failure, and bacterial and viral infections. We performed direct and indirect network meta-analyses using Bayesian models and ranked different rituximab doses using generation mixed treatment comparison. Publications were retrieved using CENTRAL, MEDLINE, EMBASE, and Science Citation Index Expanded databases from 1970 to February 2020 and analyzed. The GRADE of network meta-analysis approach specified 4 levels of certainty for a given result: high, moderate, low, and very low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 4256 patients from 21 trials, glomerular filtration rate, graft loss, antibody-mediated rejection, T-cell mediated rejection, fungal infection, bacterial infection, and CMV infection did not differ among ABOi groups treated with different rituximab doses. The effect on mortality was significantly higher in rituximab 200 to 500\u200amg, and rituximab 500\u200amg groups (odds ratios [OR] 3.5, 95% CrI: 1.3\u20139.8, and OR 3.0, 95% CrI 1.1\u20139.8), but not in rituximab 20\u200amg group (OR 0.45, 95% CrI 0.036\u20132.5). The incidence of BK virus was significantly lower in the rituximab 200-mg group than in the other groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>In ABO-incompatible kidney transplantation, low-dose rituximab is more efficacious than higher doses and reduces serious infection risks. Additional randomized controlled trials might be needed to confirm these findings due to small sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000024853","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T20:01:08Z","timestamp":1615492868000},"page":"e24853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation"],"prefix":"10.1097","volume":"100","author":[{"given":"Hee Ryong","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Leesin Hemodialysis and Intervention Clinic, Busan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kipyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoung Woo","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Leesin Hemodialysis and Intervention Clinic, Busan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6972","authenticated-orcid":false,"given":"Seun Deuk","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.krcp.2015.11.001","article-title":"Comparison of clinical outcomes between ABO-compatible and ABO-incompatible spousal donor kidney transplantation","volume":"35","author":"Park","year":"2016","journal-title":"Kidney Res Clin Pract"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1537-2995.2008.01857.x","article-title":"The critical role of plasmapheresis in ABO-incompatible renal transplantation","volume":"48","author":"Tobian","year":"2008","journal-title":"Transfusion"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.krcp.2015.08.005","article-title":"Current progress in ABO-incompatible kidney transplantation","volume":"34","author":"Koo","year":"2015","journal-title":"Kidney Res Clin Pract"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/TP.0b013e3181726849","article-title":"ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up","volume":"85","author":"Genberg","year":"2008","journal-title":"Transplantation"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.tp.0000229428.03414.b2","article-title":"ABO-incompatible kidney transplantation with and without splenectomy","volume":"82","author":"Gloor","year":"2006","journal-title":"Transplantation"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1399-0012.2010.01384.x","article-title":"The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience","volume":"25","author":"Shirakawa","year":"2011","journal-title":"Clin Transplant"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-0012.2007.00700.x","article-title":"Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients","volume":"21","author":"Grim","year":"2007","journal-title":"Clin Transplant"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00277-003-0748-4","article-title":"Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma","volume":"83","author":"Tsutsumi","year":"2004","journal-title":"Ann Hematol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/ndt\/gfw017","article-title":"The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation","volume":"31","author":"Lee","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2013.02.044","article-title":"Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"132","author":"Bae","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jep.12889","article-title":"Critical appraisal of nonrandomized studies-A review of recommended and commonly used tools","volume":"25","author":"Quigley","year":"2019","journal-title":"J Eval Clin Pract"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1744-1609.2010.00195.x","article-title":"Quality assessment tools for observational studies: lack of consensus","volume":"8","author":"Lang","year":"2010","journal-title":"Int J Evid Based Healthc"},{"key":"R20-20250504","first-page":"617","article-title":"Methodological quality assessment tools of non-experimental studies: a systematic review","volume":"28","author":"Jarde","year":"2012","journal-title":"Anales De Psicologia"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/lary.25688","article-title":"Epley and Semont maneuvers for posterior canal benign paroxysmal positional vertigo: a network meta-analysis","volume":"126","author":"Liu","year":"2016","journal-title":"Laryngoscope"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijsu.2017.09.002","article-title":"Interventions for Treating 3- or 4-part proximal humeral fractures in elderly patient: A network meta-analysis of randomized controlled trials","volume":"48","author":"Du","year":"2017","journal-title":"Int J Surg"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.transproceed.2018.01.022","article-title":"Efficacy and safety of induction therapy in kidney transplantation: a network meta-analysis","volume":"50","author":"Hwang","year":"2018","journal-title":"Transpl Proc"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.tp.0000226152.13584.ae","article-title":"Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation","volume":"82","author":"Schwartz","year":"2006","journal-title":"Transplantation"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tri.12234","article-title":"Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation","volume":"27","author":"Barnett","year":"2014","journal-title":"Transpl Int"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.transproceed.2013.09.036","article-title":"Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience","volume":"46","author":"Hatakeyama","year":"2014","journal-title":"Transplant Proc"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/ki.2013.291","article-title":"Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation","volume":"85","author":"Ashimine","year":"2014","journal-title":"Kidney Int"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000170813","article-title":"Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens","volume":"162","author":"Tanabe","year":"2009","journal-title":"Contrib Nephrol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/TP.0b013e31820f08e8","article-title":"The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction","volume":"91","author":"Fuchinoue","year":"2011","journal-title":"Transplantation"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1600-6143.2011.03830.x","article-title":"Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period","volume":"12","author":"Kohei","year":"2012","journal-title":"Am J Transplant"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/ajt.13502","article-title":"ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management","volume":"16","author":"Okumi","year":"2016","journal-title":"Am J Transplant"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.transproceed.2014.12.033","article-title":"Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation","volume":"47","author":"Nakao","year":"2015","journal-title":"Transplant Proc"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1097\/TP.0000000000000753","article-title":"Outcomes following ABO-incompatible kidney transplantation performed after desensitization by nonantigen-specific immunoadsorption","volume":"99","author":"Becker","year":"2015","journal-title":"Transplantation"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/ndt\/gfr215","article-title":"Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience","volume":"26","author":"Habicht","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/ctr.12515","article-title":"One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts","volume":"29","author":"D\u00f6rje","year":"2015","journal-title":"Clin Transplant"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.transproceed.2013.08.038","article-title":"Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea","volume":"45","author":"Hwang","year":"2013","journal-title":"Transplant Proc"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4111\/kju.2010.51.12.863","article-title":"Analysis of the results of ABO-incompatible kidney transplantation: in comparison with ABO-compatible kidney transplantation","volume":"51","author":"Jeon","year":"2010","journal-title":"Korean J Urol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/tri.12979","article-title":"Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study","volume":"30","author":"Ko","year":"2017","journal-title":"Transpl Int"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"e4249","DOI":"10.1097\/MD.0000000000004249","article-title":"Analysis of 4000 kidney transplantations in a single center: across immunological barriers","volume":"95","author":"Kwon","year":"2016","journal-title":"Medicine"},{"key":"R50-20250504","first-page":"200","article-title":"Comparative analysis of effectiveness and safety between high and low dose rituximab in ABO-incompatible kidney transplant recipients","volume":"34","author":"Moon","year":"2017","journal-title":"J Korean Soc Hosp Pharmacists"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/ctr.12759","article-title":"Borderline rejection in ABO-incompatible kidney transplantation","volume":"30","author":"S\u00e1nchez-Escuredo","year":"2016","journal-title":"Clin Transplant"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:03:11Z","timestamp":1746324191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024853"}},"subtitle":["A network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024853","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2020-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}